Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) EBITDA (2020 - 2023)

Candel Therapeutics' EBITDA history spans 4 years, with the latest figure at -$10.3 million for Q4 2023.

  • For Q4 2023, EBITDA fell 27.35% year-over-year to -$10.3 million; the TTM value through Dec 2023 reached -$38.4 million, down 10.57%, while the annual FY2024 figure was -$33.4 million, 13.08% up from the prior year.
  • EBITDA for Q4 2023 was -$10.3 million at Candel Therapeutics, down from -$8.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $1.6 million in Q4 2021 and bottomed at -$16.2 million in Q3 2021.
  • The 4-year median for EBITDA is -$8.8 million (2022), against an average of -$7.3 million.
  • The largest annual shift saw EBITDA skyrocketed 126.06% in 2021 before it crashed 607.64% in 2022.
  • A 4-year view of EBITDA shows it stood at -$6.1 million in 2020, then surged by 126.06% to $1.6 million in 2021, then plummeted by 607.64% to -$8.1 million in 2022, then fell by 27.35% to -$10.3 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's EBITDA are -$10.3 million (Q4 2023), -$8.9 million (Q3 2023), and -$9.6 million (Q2 2023).